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Diverse disease processes are today 
being directly targeted by biological 
therapeutics, and these agents are also 
being used as conjugates to conventional 
small drug molecules, in order to direct the 
drug towards specific body compartments.  
This article reviews the general aspects that 
surround the types and modes of action of 
these agents, and highlights issues that 
contribute towards development of resistance 
to biologic drugs. 
Introduction
For several years, science has been 
credited with the continual development of 
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new medicinal products to treat or manage 
a diverse range of medical conditions.   
Pharmaceutical companies have stroven to 
produce drugs with higher efficacies and 
improved safety profiles, while enhancing 
the therapeutic repertoire with agents 
capable of addressing hitherto unmet needs.
Traditionally, such drugs have largely 
consisted of low molecular weight 
molecules which were often the result of 
chemical engineering of a naturally-found 
product.  Years of research have generated 
methodologies by which such chemical 
entities can be synthesized, structurally 
characterized and analytically quantified, 
leading for example, to the establishment 
of defined protocols for shelf-life stability 
predictions, pharmacokinetic calculations 
and bio-equivalence studies.
The recent years, have seen the 
emergence of a totally new class of 
therapeutic agents, which are the result 
of large strides being accomplished in the 
biotechnology arena.  Biological drugs (or 
simply biologics), as these entities are 
known, are usually based on endogenous 
biocompounds and consist of high 
molecular weight protein structures or short 
peptides.  Rather than being chemically 
synthesized, biological drugs are usually 
produced by recombinant technologies and 
gene expression methodologies, i.e. they 
are produced in laboratories by a living 
system, and are the product of biosynthetic 
pathways.
The Food and Drug Administration (FDA) 
adopts the US Public Health Service Act 
(Section 351) definition which states that 
a biological product is a “virus, therapeutic 
serum, toxin, antitoxin, vaccine, blood, 
blood component or derivative, allergenic 
product, or analogous product, … applicable 
to the prevention, treatment, or cure of a 
disease or condition of human beings.”1  
The European Medicines Agency (EMEA) 
runs its own Biologics Working Party (BWP) 
which operates under the Committee for 
Medicinal Products for Human use (CHMP).  
The main role of the BWP is to provide 
recommendations on all matters relating 
directly or indirectly to quality aspects and 
safety in relation to quality of biological and 
biotechnological medicinal products.2  More 
recently, the CHMP has also established a 
Biosimilar Medicinal Products Working Party 
(BMWP) with the mandate of providing 
recommendations on the non-clinical 
and clinical matters relating directly or 
indirectly to similar biological medicinal 
products.3   This need has arisen from the 
fact that unlike conventional small molecule 
drugs, biologics produced by generic drug 
companies (biosimilars) may have similar 
ingredients and possess similar activities 
to the authorized product but may be 
unidentical due to differences in production 
methodologies, gene expression techniques 
etc. The complex 3D structure and highly 
specific physiological, chemical and physical 
properties of these products makes it a 
major challenge for generic producers to 
provide evidence for the biosimilarity of their 
product to that of the originator.4 
The recent years has seen significant growth in a new therapeutic 
approach to the management of disease.  Biological therapeutic agents, 
constitute a broad category of drugs, usually generated by recombinant 
techniques from living organisms.  These therapies revolutionise the 
traditional approaches to drug design and development, and regulatory 
agencies have been swift in developing the necessary structures to 
ensure their optimal use.  
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Name Type Molecular target Condition
Insulin Systemic Factor Glucose metabolism Diabetes
Erythropoietin Systemic Factor Erythropoiesis Renal failure
G-CSF Systemic Factor Neutrophils Neutropenia
Trastuzumab Humanized monoclonal Human epidermal growth Breast adenocarcinomas
 antibody factor receptor 2 (Her2)
Panitumumab Humanized monoclonal Epidermal growth factor Colorectal carcinoma
 antibody receptor (EGFR)
Gemtuzumab Conjugated humanized CD33 Acute myeloid leukemia
ozogamicin monoclonal antibody
Rituximab Chimeric CD20 B cell non-Hodgkin’s
   lymphoma
Omalizumab Humanized monoclonal IgE Asthma
 antibody
Infliximab Chimeric monoclonal TNFα Rheumatoid arthritis; 
 antibody  Crohn’s disease
Table 1.  Therapeutic biomolecules
Actions of biological drugs
The production of biomolecules has 
been extensively developed to deal with 
dysfunctional protein counterparts, 
deficient systemic production of growth 
factors, deregulated cytokine activity 
and  molecular targeting.  The high 
throughput technology available today has 
been instrumental in the identification of 
molecular mechanisms of disease with the 
potential to specifically target key molecules 
related to the condition.  Table 1 shows a 
non-exhaustive list of biotech drugs that 
are currently approved by the Food and Drug 
Adminstration (FDA) for targeted therapy.  
The production of insulin is the 
pioneering work in biotechnology.  Stanely 
Cohen and Herbert Boyer produced insulin 
in 1973 for the treatment of diabetes.   The 
human gene of insulin was isolated  and 
inserted in bacteria for large scale protein 
synthesis.5  This was the start of the use of 
recombinant technology for the production 
of pharmaceuticals.  Another success 
story in the biotechnology field is the 
production of erythropoeitin (Epo).  Epo 
is a cytokine that stimulates erythrocyte 
production in response to a low oxygen 
tension.6  The production of recombinant 
human erythropoietin (rhEpo) to treat 
anaemias associated with chronic renal 
failure has proven to be highly effective 
and safe, giving a remarkable therapeutic 
window.7,8   The main concerns associated 
with the long-term administration of 
erythropoietin are the frequent need for 
parenteral administration, the development 
of anti-Epo antibodies and the cost of 
the treatment.  Improved erythropoietic 
stimulating agents were developed through 
chemical modifications that enhance 
biological acitivity.  The hyperglycosylated 
rhEPO analogue, darbepoetin alfa contains 
five N-linked carbohydrate chains resulting 
in increased molecular weight and greater 
negative charge. The serum half life is 3 fold 
longer than rhEpo and due to the increased 
in vivo potency, the biomolecule can be 
administered less frequently.9,10  In addition, 
the  Epo mimetic peptide, Hematide™, 
binds to the erythropoietin receptor and 
elicits signal transduction giving normalised 
haemoglobin levels for a period of at least 
one month following one intravenous 
administration.11  Hematide™, currently at 
an advanced clinical trial stage, may offer 
enhanced compliance and an improved risk-
benefit ratio.
Hyperglycosylation is only one example 
of chemical modifications that have been 
developed for enhanced therapeutic window 
of biotherapeutics.  Granulocyte Colony 
Stimulating Factor (G-CSF) is another 
member of the cytokine family that 
includes Epo.  G-CSF has been engineered 
and produced as a biotech drug for the 
treatment of neutropoenia and its use has 
increased substantially due to drug-induced 
neutropoenia, associated with administration 
of the chemotherapeutic agents.   Increased 
serum retention and stability of recombinant 
G-CSF has been achieved by PEGylation, 
the covalent conjugation with polyethylene 
glycol (PEG) moiety.12       
In addition to systemic therapeutic use 
of factors and cytokines, biomolecules that 
target specific cells and the cell environment 
are gaining importance. These mainly 
consist of  antibodies with various molecular 
functions.    
Antibody-dependent cellular cytotoxicity
Unconjugated monoclonal antibodies 
are produced to target specific antigens/
receptors to elicitate an immune response.  
The recombinant, humanized monoclonal 
antibody trastuzumab specifically targets 
cells expressing the human epidermal growth 
factor receptor 2 (HER2).13  Following 
binding an antibody-dependent cell-
mediated cytotoxicity is induced.  HER2 is 
overexpressed in many adenocarcinomas, 
and promising results are being reported in 
breast adenocarcinomas.14  It is important 
to classify patients as HER2-positive to 
ensure beneficial responses.  In B-cell non-
Hodgkin’s Lymphoma the surface marker 
CD20 is targeted (Rituximab) initiating 
an antibody-dependent and complement-
dependent cell mediated cytotoxicity.15  
Inhibition of ligand binding
A human monoclonal antibody targeting 
epidermal growth factor receptor (EGFR), 
panitumumab, binds the receptor with 
high affinity, blocking receptor-mediated 
signaling by competing out the natural 
ligand.  Panitumumab inhibits the growth 
and survival of tumour cells expressing 
EGFR16 and is FDA approved for the treatment 
of metastatic colorectal cancer.    Antibodies 
can also bind to ligands and prevent ligand-
receptor binding.  Infliximab binds and 
blocks the action of tumour necrosis factor 
alpha (TNFα).  Infliximab is a chimeric 
monoclonal antibody developed in mice 
and subsequently modified into a human 
(humanized) antibody.   
Omalizumab is a recombinant DNA-
derived humanized IgG1 monoclonal 
antibody that selectively binds to human 
immunoglobulin E (IgE), thus inhibiting 
the binding of IgE to high affinity receptors 
on the surfaces of dendritic cells, mast 
cells and basophils.  It is indicated for the 
management of asthma, as it directly reduces 
the activity of IgE on the activation of these 
pro-inflammatory cells.  Moreover, de novo 
generated IgE-receptor carrying cells, are 
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exposed to lower circulating concentrations 
of free IgE, and this has been shown to 
result in a decreased expression of surface 
IgE receptors on these cells.  The drug is 
administered sub-cutaneously in repeated 
doses, to patients who satisfy specific 
diagnostic criteria, and clinical studies have 
shown this to result in a significant reduction 
of exacerbations of asthma. 
Conjugated antibodies
Genetically engineered antibodies or 
antibody fragments have the capacity 
to target tumour cells or the tumour 
environment and facilitate a response by 
directing a chemotherapeutic drug or by 
recruiting the immune system, as evidenced 
in pre-clinical studies. The conjugation 
of a cytotoxic agent to a recombinant 
antibody results in the specific binding of 
the antibody to targeted cells, followed by 
internalization and the delivery of the agent. 
The chemotherapeutic drug, Gemtuzumab 
ozogamicin consists of a recombinant, 
humanized anti-CD33 monoclonal 
antibody attached to the cytotoxic agent 
calichaemicin.  The antibody targets CD33-
positive leukemic blasts, followed by delivery 
of calicheamicin which binds to the minor 
groove of DNA causing a double stand break.17
Immunocytokines are fusion proteins 
that recruit the immune system to tumour 
cells as is the case of  IL2 fusions with 
EpCAM and L19.   The fusion protein 
(tucotuzumab celmoleukin) concentrates 
the active interleukin-2 (IL-2) molecule at 
tumour tissue expressing the cell adhesion 
molecule, EpCAM.18  The L19-IL2 is a 
fusion protein composed of an antibody 
fragment against a fibronectin isoform 
present in neovascularisation.19  This allows 
targeting of angiogenesis.  In all these 
cases the localized IL-2 molecule stimulates 
a cytotoxic T-cell antitumour immune 
response.   Specific targeting of cells through 
conjugated antibody technology is envisaged 
to emerge as a major biological therapeutic 
approach.
    
Resistance to biological 
therapeutic agents
Regular use of conventional drugs is well 
known to often lead to gradual development 
of tolerance, and the mechanisms of this 
often involve events which occur at the 
receptor level. A distribution of observed 
efficacies in a given population is also often 
evident, with a proportion of individuals 
sometimes being clinically unresponsive 
to a specific therapeutic agent.  Biological 
therapies may also exhibit similar effects, 
though the mechanisms are usually more 
complex.
Protein expression levels
The expression levels of various 
endogenous proteins may be altered 
in disease, and may influence the 
efficacy of therapeutic biological agents.  
Overexpression of the membrane-associated 
glycoprotein mucin-4 (MUC4) for example, 
can mask the HER2 receptor, and prevent 
binding of trastuzumab.  Cell culture-based 
experiments have shown that increased 
signalling from HER2/HER3 and HER2/EGFR 
complexes	in	HER2+ve	cells,	contribute	to	
development of resistance to trastuzumab.20  
The situation with interferon-α (IFNα), 
used therapeutically to target several 
neoplasms such as chronic myeloid leukaemia 
(CML), is more complex.  In vitro work on 
IFNα-resistant cell lines, has shown these 
cells to show altered expression of 39 
different genes, which are involved in such 
diverse functions as signal transduction, 
apoptosis, transcriptional regulation and cell 
growth.21
Besides their direct role in the transfer 
of various drug molecules across cell 
membranes, drug transporters, such as 
P-glycoprotein (P-gp), may also influence 
biological therapeutic agents through 
indirect mechanisms.  Tumour Necrosis 
Factor-alpha (TNFα)-based therapies are 
used to induce cell-death (apoptosis) in 
anti-cancer therapeutics.
In order for these therapies to exert 
their apoptotic function, another family of 
proteins called caspases must come into play. 
P-gp, which is occasionally overexpressed 
in some leukaemias and solid tumours, 
has been recognised to inhibit caspase-3 
activation, and therefore downstream 
apoptotic pathways, causing an effect that is 
clinically observed as a resistance to TNFα-
based therapies.22
Genetic variability 
Resistance to protein or peptide-based 
therapies may also arise from the presence 
of DNA variability in specific genes, and 
several examples of this exist in literature.   
Of interest is the association of oncogenic 
mutations in the phosphoinositide 3-kinase 
(PI3K) pathway and trastuzumab resistance.23 
This is in line with the observations 
that trastuzumab action involves the 
inactivation of the PI3K pathway.24  Hence 
characterisation of the activity of the PI3K 
pathway is a potential predictive biomarker 
panel for resistance associated with 
trastuzumab use.
Immunogenicity
All biological therapeutic agents are 
potentially immunogenic, and antibodies 
to these agents may be detectable in 
some patients.  For example about 6% of 
rheumatoid arthritis patients on adalimumab 
have detectable levels of antibodies to 
the drug, while in the case of infliximab, 
antibodies are detected in about 11% of RA 
patients.  Indeed, this was proposed as an 
explanation for the observed progressive 
decrease in infliximab efficacy over time, 
which is not clinically observed with 
adalimumab.25
Omalizumab, a recombinant humanized 
monoclonal antibody to immunoglobulin 
E (IgE) has been recently licensed for 
anti-asthma therapy. Rare hypersensitivity 
reactions have been reported following 
use of this drug, and these include 
bronchospasm, hypotension, syncope, 
urticaria, and angioedema of the throat or 
tongue.  Such reactions have been reported 
to occur as early as after the first dose 
of omalizumab, but also beyond 1 year 
after beginning regularly administered 
treatment.26,27
Other mechanisms
It is often difficult to suitably explain 
the causes of drug resistance. For example, 
studies have shown that the efficacy of 
infliximab appears to decrease over time 
with continuous usage, and this clinical 
observation is evident after 6 months of 
treatment.  
However, this has not been reported 
to occur with adalimumab – another TNFα 
antibody, or etanercept - a TNFα inhibitor 
that mimics the actions of endogenous 
soluble TNFα receptors.  It has been 
suggested that lymphotoxin-α (LTα), a 
member of the TNFβ family, which has been 
identified in the synovial fluid of infliximab-
resistant RA patients, may have a role in the 
development of this resistance, but the exact 
mechanism remains to be elucidated.28
Conclusion
The recent years have seen a rapid 
growth in the development of new biological 
drugs, as therapeutic modalities that offer 
improved outcomes over conventional 
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•	 Biological	agents	offer	novel	approaches	to	disease	management,	due	to	their	ability	to	
interfere with specific processes which cannot be targeted by conventional molecules.
•	 These	drugs	may	be	designed	to	emulate	endogenous	biocompounds,	inhibit	specific	
proteins, recruit endogenous molecules to specific tissues or target conventional agents 
to their sites of action.
•	 Similar	to	conventional	therapies,	resistance	to	biological	therapeutic	agents	may	also	
occur, though the mechanisms may often be different.
•	 Though	the	direct	cost	of	these	therapies	is	higher	than	conventional	agents,	their	
optimal economic use should include an assessment of improved efficacies, decreased 
long term medical care costs, improved quality of life and increased economic 
productivity.
Practice points
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